4//SEC Filing
CURIS INC 4
Accession 0001181431-07-038898
$CRISCIK 0001108205operating
Filed
Jun 7, 8:00 PM ET
Accepted
Jun 8, 2:41 PM ET
Size
12.3 KB
Accession
0001181431-07-038898
Insider Transaction Report
Form 4
CURIS INCCRIS
Qian Changgeng
VP, Research & Preclinical Dev
Transactions
- Award
Non-qualified stock option (right to buy)
2007-06-06+70,233→ 70,233 totalExercise: $1.39Exp: 2017-06-06→ Common stock (70,233 underlying) - Award
Qualified stock option (right to buy)
2007-06-06+71,942→ 71,942 totalExercise: $1.39Exp: 2017-06-06→ Common stock (71,942 underlying) - Award
Qualified stock option (right to buy)
2007-06-06+79,767→ 79,767 totalExercise: $1.39Exp: 2017-06-06→ Common stock (79,767 underlying) - Award
Non-qualified stock option (right to buy)
2007-06-06+78,058→ 78,058 totalExercise: $1.39Exp: 2017-06-06→ Common stock (78,058 underlying)
Footnotes (2)
- [F1]Options in the aggregate will vest 25% on the one-year anniversary grant date, or June 6, 2008. Remaining options will vest at 6.25% each successive three-month period, with non-qualified options vesting first. Options will be fully vested four years from the grant date.
- [F2]Common stock subject to stock option award shall become exercisable on December 6, 2012 or upon the consummation of a collaboration, licensing or other similar agreement regarding the Targeted Cancer Drug Development Platform that includes an up-front cash payment of at least $10 million. For clarity, the cash payment shall be attributable to a nonrefundable license fee or other similar payment and shall not include an equity investment in Curis and any vesting is subject to such Executive Officer's continued service with the Curis.
Documents
Issuer
CURIS INC
CIK 0001108205
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001108205
Filing Metadata
- Form type
- 4
- Filed
- Jun 7, 8:00 PM ET
- Accepted
- Jun 8, 2:41 PM ET
- Size
- 12.3 KB